Medicare AdvantageCoverageMedium impact
MA08.022s, Rituximab (Rituxan®) Infusion and Related Biosimilars, and Rituximab/Hyaluronidase Human for Subcutaneous Injection (Rituxan Hycela®)
Independence Blue Cross·Oncology, Hematology, Rheumatology·Pharmacy
Effective date
Oct 29, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.022s for Rituximab (Rituxan) infusion, related biosimilars, and subcutaneous Rituxan Hycela has been reissued effective October 29, 2025. This is a policy update that may affect coverage criteria, prior authorization requirements, or billing procedures for these specialty medications used in oncology and rheumatology treatments.
Action Required
By October 29, 2025: Billing team must review the complete updated policy MA08.022s at the provided URL to identify any changes to coverage criteria, prior authorization requirements, or billing procedures for Rituximab products. Update billing system settings and staff training materials accordingly to ensure compliant claims submission for Medicare Advantage patients receiving these treatments.